24.3 C
Vientiane
Tuesday, August 26, 2025
spot_img
Home Blog Page 166

Karjengon Wu’s Unique Aesthetic Language: Taiwanese Jewelry Artist Shines on the Global Stage

TAIPEI, Aug. 6, 2025 /PRNewswire/ — Taiwanese jewelry artist Karjengon Wu has forged a distinctive design language that seamlessly integrates art, culture, aesthetics, and brand management. With this multifaceted creative power, he has risen to prominence in the international jewelry scene. His works are not merely accessories, but wearable art pieces—cultural vessels that transcend borders—earning acclaim and admiration across the global fashion world.



Wu is the founder of T.THREE Jewelry, a brand he co-created with design partner Yi-Wen Lin. Together, they have produced numerous captivating collections favored by global dignitaries and social elites. Notable collectors of his work include Palau‘s Goodwill Ambassador Ms. Chia-Ju TsaiMrs. Paine, wife of the Haitian Ambassador, and Abigail Beatrice, First Secretary of the Eswatini Embassy—each representing the international appeal of Wu’s creations.


Mayor Bertrick of Moret-sur-Loing, France, personally collected one of Wu’s signature pieces, praising its exquisite craftsmanship and the profound beauty of Eastern design. He described the work as a “cultural bridge” between France and Taiwan. Madame Dominique, Chair of the French Association of Painters and Calligraphers, also collected Wu’s award-winning piece “Elegant Orchid Spirit, which received honors at the International Orchid Handicraft Competition—further affirming Wu’s artistic impact on the global stage.


Wu’s creations have also been embraced by the fine art community. Ho Wen-Chi, a nationally honored painter recognized by Taiwan’s Ministry of Culture, is a devoted wearer of Wu’s pieces, commending the harmonious balance of colors and gemstones. The late master of ink painting, Lee Chi-Mao, also collected Wu’s jewelry and inscribed a personalized calligraphy piece in tribute:
“Mr. Karjengon—Master of Exquisite Eastern Craftsmanship,” adding a layer of artistic resonance to Wu’s design legacy.

Karjengon Wu’s design language is highly distinctive. Whether working in minimalism, Baroque, naturalism, futurism, or ethnic styles, each collection presents a uniquely interpreted aesthetic. He boldly incorporates unconventional materials such as wood, shells, resin, and recycled elements, utilizing wax carving, micro-sculpting, and mixed media to break free from traditional jewelry frameworks.


His works have been showcased at numerous international exhibitions in cities such as Paris, Beijing, Chongqing, and Tokyo, highlighting Taiwan’s creative spirit and rich design diversity on a global scale—enhancing the island’s visibility and influence in the realm of cultural diplomacy.

Selected International Exhibitions & Events:

  • 2012 – Greater China Jewelry Designers Joint Exhibition, Beijing, China (Taiwan Representative)
  • 2012 – China International Jewelry Masters Forum, Beijing Caibai
  • 2013 – Shenzhen International Cultural Industries Fair, Jewelry Pavilion
  • 2014 – East-West Art Exchange Exhibition at the Louvre, Paris
  • 2014 – Awarded artist in the Taiwan Tour of the Louvre’s East-West Art Exhibition (Kaohsiung)
  • 2015 – International Art Expo at Pierre Cardin Art Center, Paris – attended by Laotian princess and 8th arrondissement mayor Jeanne d’Hauteserre
  • 2017 – Jewelry showcase and forum hosted by China’s Taiwan Affairs Office in Chengdu
  • 2019 – Karjengon Wu & Yi-Wen Lin Jewelry Duo Exhibition and Runway Show at Far Eastern Museum THE ONE
  • 2022 – Cross-disciplinary showcase combining traditional cheongsam and jewelry at Lin Palace, Kaohsiung
  • 2023 – T.THREE Jewelry Show at Kaohsiung Marriott Hotel – featuring Miss Asia Taiwan 3rd runner-up Yu Hsiao-Han wearing Wu’s Louvre gold-winning piece
  • 2024 – Jewelry runway show at the Neo-Classical Ladies Club President Handover Ceremony at Lin Palace
  • 2025 – Karjengon Wu & Yi-Wen Lin’s stunning runway showcase at Lin Palace again highlighted in a prestigious handover ceremony

A special highlight: Former French Prime Minister Jean-Pierre Raffarin personally visited Wu’s exhibition at the Louvre in 2014 and gave high praise to his jewelry artworks.

Staying true to his mission—Let Taiwanese design shine confidently on the global stage—Karjengon Wu continues to root his work in Eastern aesthetics while merging them with contemporary creative expressions. His culturally enriched jewelry art continues to captivate collectors and audiences around the world.

  • Brand Information

T.THREE Jewelry
Facebook: https://www.facebook.com/profile.php?id=100063912950648

Original link: https://www.t3-news.com/news_detail.php?NewsID=12708&NewsTitle=%E7%8F%A0%E5%AF%B6%E8%A8%AD%E8%A8%88%E5%B8%AB%E5%90%B3%E4%BD%B3%E6%A5%A8Karjengon%E5%89%B5%E6%84%8F%E8%BB%9F%E5%AF%A6%E5%8A%9B%E5%90%B8%E5%BC%95%E5%9C%8B%E9%9A%9B%E7%9B%AE%E5%85%89

The U.S. FDA Granted Fast Track Designation to Dizal’s Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL
  • Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an objective response rate of 84.2% in heavily pretreated CLL/SLL patients

SHANGHAI, Aug. 6, 2025 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its Birelentinib (DZD8586) for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

Patients with CLL/SLL treated with a BTK inhibitor or a BCL-2 inhibitor often relapse or progress due to two major resistance mechanisms: BTK C481X mutations and BTK-independent activation of BCR signaling pathway. No targeted therapy currently addresses both mechanisms, posing an urgent clinical challenge. Although BTK degraders have shown encouraging anti-tumor activity in early CLL/SLL clinical studies, mutation-mediated resistance has already been reported, and degrader-associated toxicities may limit their long-term clinical application.

Birelentinib is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration. It has high selectivity against other TEC family kinases (TEC, ITK, TXK and BMX). By targeting both BTK and LYN, it blocks both BTK-dependent and -independent BCR-signaling pathways, effectively inhibiting tumor growth of B-cell non-Hodgkin lymphomas (B-NHLs).

The Fast Track Designation is supported by data from a pooled analysis of two phase I/II studies of birelentinib in CLL/SLL patients previously treated with covalent/non-covalent BTK inhibitors and BTK degraders. The results were presented at 2025 European Hematology Association (EHA) Annual Congress and featured in oral presentations at both the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 18th International Conference on Malignant Lymphoma (ICML).

Birelentinib demonstrated significant anti-tumor efficacy in heavily pretreated CLL/SLL patients with an objective response rate (ORR) of 84.2%, with a good safety profile. Tumor responses were observed irrespective of prior treatment with covalent/non-covalent BTK inhibitors, BTK degraders, or BCL-2 inhibitors, including in patients harboring classic BTK resistance mutations (C481X) as well as other BTK mutations, such as kinase-dead mutations. Responses were durable, with an estimated 9-month duration of response (DOR) rate of 83.3%.

“The granting of Fast Track Designation underscores the U.S. FDA’s recognition of birelentinib’s potential to address an unmet medical need in patients with CLL/SLL,” said Dr. Xiaolin Zhang, CEO of Dizal. “We look forward to working closely with the FDA to accelerate the global clinical development of birelentinib and bring this treatment option to patients as quickly as possible.”

Fast Track Designation is an FDA program designed to facilitate the development and expedite the review of drugs for serious conditions that address unmet medical needs. The designation enables for frequent FDA interactions and may allow for rolling revie, priority review, or accelerated approval if criteria are met.

About Birelentinib (DZD8586)

Birelentinib is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed as a potential treatment option for B-cell non-Hodgkin lymphoma (B-NHL). 

While Bruton’s Tyrosine Kinase (BTK) inhibitors have been approved for the treatment of B-NHL, resistance can arise through two major mechanisms: the BTK C481X mutation and BTK-independent BCR signaling pathway activation. Currently, there is no targeted therapy available to address both resistance mechanisms, posing an urgent clinical challenge. Although BTK degraders have shown encouraging efficacy in early clinical studies, mutation-related resistance has been reported, and degrader-related toxicities may affect long-term clinical application. 

Birelentinib has high selectivity against other TEC family kinases (TEC, ITK, TXK and BMX). By targeting BTK and LYN, it blocks both BTK-dependent and -independent BCR-signaling pathways, effectively inhibiting tumor growth of B-NHLs in cell lines and in animal models. In clinical studies, birelentinib exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL.

In August 2025, birelentinib was granted Fast Track Designation by the U.S. FDA for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with multiple assets in global pivotal studies and two leading assets: ZEGFROVY, approved in both the U.S. and China, and golidocitinib, approved in China. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or X.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Contacts

Investor Relations: ir@dizalpharma.com
Business Development: bd@dizalpharma.com
Media Contact: pr@dizalpharma.com

Stavtar Solutions Secures $55 Million from Elephant to Accelerate Growth and Scale Operations

NEW YORK, Aug. 6, 2025 /PRNewswire/ — Stavtar Solutions, a leading provider of business spend management and expense allocation SaaS for complex businesses such as alternative asset managers, today announced a Series A investment of $55 million from Elephant. The minority investment will fuel the next phase of expansion for the platform that has revolutionized how complex businesses are managing their business spend, expense allocations, vendors, contracts, budgets, payments, and more. It will drive continued product innovation, expansion of integrated payment capabilities within its flagship product StavPay, as well as hiring to meet rapidly increasing demand.

Co-founded by Steven Petersen and Avtar Batth, a former CFO and CTO respectively, Stavtar was created to solve a problem they lived firsthand: the overwhelming reliance on manual processes and spreadsheets to manage business spend and expense allocations within alternative asset management. With years of navigating operational bottlenecks and fragmented systems, they set out to build a modern, customizable, data-driven platform designed specifically for the needs of finance and operations teams at hedge funds, private equity, family offices, and other complex businesses. Stavtar has grown over 1300% in the past three years and is now the platform of choice for more than 100 alternative asset managers overseeing $2.4 Trillion in AUM. The StavPay platform powers automated workflows for vendor, contract and invoice management, expense allocations, third party payments, budgets, tax filings, custom reporting, and more. It turns their clients’ entire process into approve or reject, while giving them insights into their business like never before, in real time.

“We built Stavtar to fix what we could not ignore – outdated, manual, disconnected financial workflows holding back high-performing teams,” said Steven Petersen, Co-Founder of Stavtar. “Our partnership with Elephant empowers us to focus on what matters most – delivering innovative, enterprise-grade solutions to our clients. We are excited to grow faster, go further, and continue pushing the boundaries of what is possible in software for complex businesses.”

“We engineered Stavtar to address the real pain points faced by complex businesses,” said Avtar Batth, Co-Founder of Stavtar. “This investment enables us to accelerate the development of a scalable, intelligent system designed specifically for the financial and operational realities of alternative asset managers and other sophisticated enterprises.”

This milestone empowers Stavtar to:

  • Drive innovation across its portfolio of solutions.
  • Grow the engineering, implementation, customer success, and sales teams. 
  • Advance its integrated payments platform, including virtual card and vendor payment capabilities.
  • Deepen AI and mobile capabilities to put business spend control and insights directly in the hands of CEOs, CFOs, and finance teams. 
  • Expand footprint into verticals adjacent to alternative asset management and other similarly complex businesses.

Peter Fallon, Partner at Elephant, will join Stavtar’s board of directors. “Steve and Avtar have built a category-defining platform that solves the complex, high-value challenges confronting some of the most discerning firms in finance,” said Fallon. “We are thrilled to support Stavtar’s vision and help scale its impact through continued market growth.”

With offices in New York, Dallas, London, Mumbai, and Bengaluru, Stavtar is scaling with focus, giving finance teams the tools they need to eliminate manual work, reduce operational risk, increase productivity, and move faster.

About Stavtar

Stavtar is the premier provider of business spend management and expense allocation SaaS solutions built for the Office of the CFO in complex businesses like alternative asset management. Headquartered in New York, with a global footprint spanning Dallas, London, Mumbai, and Bengaluru, Stavtar was founded by seasoned professionals from the alternative asset management industry.

Our flagship business spend management and expense allocation platform, StavPay, empowers over 100 leading alternative asset managers, collectively overseeing more than $2.4 trillion in AUM. 

To learn more, visit www.stavtar.com

About Elephant

Elephant is a venture capital firm focused on the enterprise software, consumer internet, and mobile markets.

BEST SPAC I Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Rights Commencing August 7, 2025

HONG KONG, Aug. 6, 2025 /PRNewswire/ — BEST SPAC I Acquisition Corp. (Nasdaq: BSAAU) (the “Company”) today announced that, commencing August 7, 2025, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and rights included in the units.

No fractional rights will be issued upon separation of the units and only whole rights will trade. The Class A ordinary shares and rights that are separated will trade on The Nasdaq Capital Market under the symbols “BSAA” and “BSAAR,” respectively. Those units not separated will continue to trade on The Nasdaq Capital Market under the symbol “BSAAU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A ordinary shares and rights.

A registration statement on Form S-1 (File No. 333-286237) (the “Registration Statement”) relating to the securities sold in the initial public offering, as amended, was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on June 12, 2025. The offering was made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, by telephone at (212) 895-3745 or by email at syndicate@maximgrp.com, or by accessing the SEC’s website, www.sec.gov

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BEST SPAC I Acquisition Corp.

BEST SPAC I Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. BEST SPAC I Acquisition Corp. intends to focus on businesses in the consumer goods sector.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the anticipated use of the net proceeds and search for an initial business combination. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.

Newborn Town Issues Positive Profit Alert for First-Half 2025: Adjusted Operating Profit Surpasses RMB 600 Million, while the Profit Attributable to the Company’s Equity Shareholders Increases over 108% YoY

HONG KONG, Aug. 6, 2025 /PRNewswire/ — On August 6th, Newborn Town (9911.HK) released a positive profit alert for the first half of 2025. The Group achieved rapid revenue expansion alongside a substantial increase in profit, driven by the dual-engine growth of its social networking and innovative businesses.

For the six months ended June 30th, 2025, the Group’s total revenue is estimated to reach RMB 3,135 million and RMB 3,215 million, representing a year-on-year increase of approximately 38% to 41.5%. Profit attributable to equity shareholders of the company is expected to range from RMB 470 million to RMB 510 million, reflecting a year-on-year increase of approximately 108.9% to 126.7%. Adjusted EBITDA is projected to range from RMB 630 million to RMB 670 million, showing a year-on-year increase of 40.6% to 49.6%.


AI Applications Intensify: Products with “Tens of Millions” Monthly Recharge Set to Expand in Three Years

In the first half of 2025, the social networking business delivered robust profit growth. According to the announcement, the growth was driven by the continued expansion of diversified social products supported by AI technology, as well as the complete consolidation of NBT Social Networking Inc.’s financials following the acquisition of its non-controlling interests in December 2024.

Newborn Town’s global product portfolio continued to scale across markets. While flagship products like MICO and YoHo remained as steady contributors of profit and cash flow, the revenue contribution from newer products such as SUGO and TopTop continued to rise in the first half of 2025.

During this period, Newborn Town also made significant strides in key markets like MENA. Through refined operational strategies, Newborn Town has enhanced user experience and monetization efficiency, further unlocking the market’s vast potential. Meanwhile, the company has been deepening its “product replication + country replication” strategy to actively explore new markets. Currently, some products have already successfully entered these new regions.

AI continues to empower the Group’s products with deeper applications across operational scenarios. The self-developed multimodal algorithm Boomiix continues to be upgraded, enhancing social matching precision and intelligent operations, particularly effective in user acquisition across new markets and long-tail user engagement. Each key part of the R&D function of the company also applied AI technology to improve efficiency. For example, the self-development internal AIGC tools adopted by the design team have significantly enhanced efficiency in areas like virtual gift remix, animation effects addition and graphic design.   

With deeper market understanding, stronger localized operations, and broader AI integration, the Group is accelerating the pace of blockbuster product incubation. Over the next three years, two new products under development are expected to reach monthly recharge exceeding USD 10 million, further expanding the scale of the social networking business.

The Group’s diverse-audience social networking business sustained solid development in global markets. Through iterating social features and deepening content ecosystems, user experience and engagement depth under the business segment further improved. In addition, brand campaigns and social responsibility initiatives have elevated overall brand awareness and influence. At the beginning of 2025, HeeSay GALA events were held in Thailand and the Philippines, encouraging users to co-create vibrant, diverse community ecosystems with HeeSay.

Innovative Business Accelerated Growth, with Global Expansion Entering a New Phase

In the first half of 2025, as the moat around the social networking business continues to strengthen, Newborn Town’s second growth curve – powered by quality games and social e-commerce – has become increasingly mature. Revenue from the innovative business is expected to reach RMB 335 million to RMB 355 million, up approximately 65.0% to 74.9% year-on-year.

According to the announcement, the growth was driven by solid traffic monetization and social e-commerce performance, as well as contributions from quality games, which began monetizing in Q4 2024. 

Social e-commerce saw a notable performance boost, driven by upgraded user services, diversified business ecosystem, and expanded acquisition channels. In the first half of 2025, Heer Health achieved steady growth, further solidifying its leadership in the sexual health service and HIV prevention and control segments.

Following its initial revenue contribution last year, Newborn Town’s quality games segment officially entered a profit-generating phase in 2025. Flagship product, Alice’s Dream: Merge Games moved into long-term operation, delivering steady returns. Leveraging its experience in the merge-game category, the Group has significantly shortened development cycles. Key metrics such as user retention and ARPU have remained strong, while new game development is progressing smoothly.

In June 2025, Newborn Town officially established its global headquarters in Hong Kong, marking another milestone in the company’s worldwide expansion and signaling a new chapter in its globalization strategy.

Moving forward, the company will leverage Hong Kong as a strategic global hub, working closely with its R&D and operations centers worldwide. Through technological innovation and localized operations, Newborn Town will further expand its global business and create positive emotional value to users worldwide.

Moon Ocean Asia Teams Up with EASTAR YACHT to Propel Chinese Yacht Brand onto the Global Stage

SHENZHEN, China, Aug. 6, 2025 /PRNewswire/ — A report from tirechina.

Moon Ocean Asia Group has officially entered into a strategic partnership with EASTAR YACHT, becoming the exclusive distributor for EASTAR YACHT across Hong Kong and Southeast Asia. This collaboration marks a pivotal moment in the internationalization of Chinese yacht manufacturing, paving the way for homegrown brands to gain greater recognition on the global stage. By joining forces, both parties aim to redefine the identity of Chinese-made yachts through innovation, artisanal quality, and wider market outreach.

Moon Ocean Asia Teams Up with EASTAR YACHT to Propel Chinese Yacht Brand onto the Global Stage
Moon Ocean Asia Teams Up with EASTAR YACHT to Propel Chinese Yacht Brand onto the Global Stage

Boasting over two decades of experience representing premier European and American yacht brands, Moon Ocean Asia Group has a proven track record of successfully introducing globally renowned names such as Italy’s Azimut Yachts and America’s Chris Craft to the Asian market. With a strong brand reputation, extensive industry resources, and well-established global sales and service networks, the group holds significant influence within China’s domestic yacht industry.

As China’s yacht manufacturing capabilities have advanced rapidly, the group has strategically shifted its focus towards expanding exports of Chinese-made yachts. The collaboration with EASTAR YACHT represents a key milestone in this strategic transformation.

EASTAR YACHT, a rapidly rising star in the industry, leverages its advantageous location within China’s largest yacht industrial park to fuel its growth. The company offers a diverse portfolio ranging from 46-foot leisure yachts to 116-foot superyachts certified for ocean voyages. Notable models include the 56-foot catamaran power yacht—measuring 17.12 meters in length and 8.38 meters in width—that combines comfort and functionality; the 66-foot catamaran, at 20.20 meters long and 9.80 meters wide, designed for large-scale business receptions; the 80-foot luxury business yacht (23.99 meters) tailored for high-end corporate events; and the 116-foot superyacht (35.82 meters), a testament to China’s cutting-edge yacht-building expertise that has already earned widespread market acclaim.

Beyond its diverse product range, EASTAR YACHT places strong emphasis on technological innovation, with a particular focus on new energy solutions. The company has assembled a team of industry-leading experts dedicated to exploring clean energy applications in yachting, thereby securing a critical technological advantage in the global market.

Moon Ocean Asia Group has committed to providing comprehensive support for EASTAR YACHT—including pre-sales, sales, after-sales services, as well as yacht management and leasing—through its extensive global network. This partnership aims to help the Chinese brand establish a strong presence in Southeast Asia and beyond. Industry experts highlight that by combining EASTAR’s manufacturing expertise with Moon Ocean’s international distribution channels, this collaboration has the potential to transform the competitive dynamics of the global yacht market.

Early signs are encouraging, with EASTAR YACHT experiencing a steady increase in overseas orders. Looking forward, deeper cooperation is expected to enable more Chinese-made yachts—manufactured in Zhuhai—to make a significant impact across Asia and international waters, further enhancing China’s success story in manufacturing exports.

GIBO Click Powers Advanced Audience Intelligence and Monetization Logic in Successful Trial with CoolShort

HONG KONG, Aug. 6, 2025 /PRNewswire/ — GIBO Holdings Ltd. (NASDAQ: GIBO), a leader in AI-driven content monetization infrastructure, today announced the successful trial of GIBO Click on CoolShort, one of the newest global short-drama platforms focused on interactive entertainment experiences.

Launched in June 2025, CoolShort is dedicated to delivering immersive and interactive short-drama content to global audiences. The platform primarily serves North America, Japan, Korea, and Southeast Asia, offering 1-3 minute vertical short dramas across multiple genres. It supports a flexible monetization structure, including in-app purchases (IAP), in-app advertising (IAA), and subscription memberships, enabling a diverse range of revenue models.

As of July 2025, CoolShort has:

  • 400,000 total users
  • 50,000 daily active users (DAU)
  • 12 million cumulative views

Beyond Payments: Intelligent Engagement Analytics with GIBO Click

Unlike previous trials that focused primarily on payment settlement, the CoolShort test prioritized audience analytics and adaptive monetization strategies, highlighting GIBO Click’s broader capabilities. Key functions validated during the trial include:

  • Behavioral Insights Dashboard: Real-time analysis of viewing patterns, retention data, and user engagement metrics
  • Dynamic Pricing Algorithms: Testing content-driven price adjustments for premium episodes and bundles
  • Global Monetization Readiness: Ensuring scalable, multi-currency infrastructure to serve diverse regional markets
  • Performance-Based Recommendations: Leveraging AI data to enhance personalized content discovery

Strategic Impact for Short-Drama Platforms

With the short-drama industry becoming a global entertainment phenomenon, platforms need data-driven strategies to boost user retention, optimize monetization, and deliver premium content experiences. GIBO Click positions itself as the ultimate backend engine for this transformation—linking audience intelligence with monetization logic.

“The CoolShort trial demonstrates that GIBO Click goes beyond financial settlement—it provides platforms with actionable insights for smarter content strategies and revenue growth paving a strong foundation towards the company’s next milestone,” said a GIBO representative.

About GIBO Holdings Limited

GIBO Holdings Ltd. is a unique and integrated AIGC animation streaming platform with extensive functionalities provided to both viewers and creators that serves a broad community of young people across Asia to create, publish, share and enjoy AI-generated animation video content. With over 86 million registered users and advanced AI-powered tools, GIBO seeks to redefine the landscape of digital content creation.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the Company’s ability to scale and grow its business, the Company’s advantages and expected growth, the Company’s ability to source and retain talent, and the Company’s cash position, as applicable. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These statements involve risks, uncertainties and other factors that may cause the Company’s actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained in this press release, the Company cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. The forward-looking statements in this press release represent the views of the Company as of the date of this press release. Subsequent events and developments may cause those views to change. Except as may be required by law, the Company does not undertake any duty to update these forward-looking statements.

Contact Information

Investor Relations:
Bill Zima
ICR, Inc.
William.zima@icrinc.com 

Media Relations:
Edmond Lococo
ICR, Inc.
Edmond.Lococo@icrinc.com

For more information and the latest updates, please visit:
https://www.globalibo.com/gibo-click/

 

OneConnect and Inspur Announce Strategic Partnership to Accelerate Global AI-Powered Digital Transformation

HONG KONG, Aug. 6, 2025 /PRNewswire/ — OneConnect Financial Technology, an associate company of Ping An Group, has entered into a strategic partnership with Inspur Enterprise Cloud and Inspur Computer Technology. The collaboration was formalized through a signing ceremony in July 2025.

This alliance marks a pivotal step in OneConnect’s mission to accelerate global digital transformation and redefine AI-powered business solutions. By combining our complementary strengths, the partnership aims to deliver unparalleled value to finance, government, and enterprise clients worldwide—especially those with stringent data privacy requirements and urgent demand for generative AI capabilities.

Inspur Enterprise Cloud, one of China’s earliest cloud service providers and a leader in the country’s industry cloud sector, offers advanced technologies and services in cloud computing, big data, and artificial intelligence. It delivers full-stack cloud computing solutions to sectors including manufacturing, energy, and finance, and has co-founded the Cloud Sail Alliance to promote industrial digital transformation through customized “cloud + AI” services.

Inspur Computer Technology holds a 14% market share in innovation technology servers (No.1 in the industry as of 2024), offering a comprehensive portfolio that includes high-end, commercial, and portable computers, as well as a full range of servers—computing, storage, AI, and liquid-cooled systems—serving sectors from government to finance.

As a leader in fintech innovation, OneConnect boasts a suite of more than 12 AI-powered business applications tailored for the financial industry. Its impact runs deep in Hong Kong’s financial ecosystem: over 50% of Hong Kong’s retail banks have adopted our AI-based image recognition technology to combat fraud and support their full digital transformation journeys.

Our deepfake detection and anti-fraud technologies are trusted by the Hong Kong government to protect critical public services from evolving digital threats. Major banks, including one of the city’s leading note-issuing institutions, have leveraged our generative AI capabilities to enhance chatbot services and customer support.

OneConnect’s AI-powered wealth management solutions—including investment advisory, asset allocation, and relationship manager (RM) script generation—have driven strong demand in the growing market for AI-driven wealth management. With mature local delivery capabilities and unique cross-boundary data reference authorization in Hong Kong, OneConnect serves as a vital bridge for global technology integration in the region.

By combining OneConnect’s AI and fintech expertise with Inspur’s strengths in cloud computing, big data, and AI hardware, the partnership aims to:

  • Share resources across finance, government, healthcare, and other sectors to develop customized, innovative AI solutions.
  • Leverage the success of OneConnect’s applications and Inspur’s infrastructure to scale benchmark projects globally, particularly along the Belt and Road Initiative.

This partnership underscores our joint commitment to shaping the future of global AI computing power and digital transformation—delivering unprecedented value to clients across industries and regions.